Therapies of resistant exudative pleuritis

In Russia, annually more than 100,000 people are diagnosed with tumor pleuritis. Resistant cancerous pleuritis is often caused by lung cancer (35 %), breast cancer (23 %), ovarian cancer and lymphomas (10 %). Pleuritis in malignant neoplasms often indicates the spread of the process through pleura. At the same time, systemic therapy does not always help patients. Radical treatment for malignant pleural effusion is gradually being replaced by new minimally invasive methods. Prolonged drainage of the pleural cavity in exudative pleuritis increases the risk of infection, which contributes to the development of pleural empyema. In order to eliminate the exudate, talc, tetracycline, and Betadine solutions are introduced into the pleural cavity through the drainage, the efficacy being 60 to 90 %. Thus, a new method for drug administration into the pleural cavity, which helps to eliminate resistant exudative pleuritis, remains relevant.